|
| 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one Basic information |
Product Name: | 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one | Synonyms: | 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one;6-Bromo-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one;4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate;6-Bromo-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;Palbociclib-013;6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one;Palbociclib impurity 16/6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin- 2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one;Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-bromo-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- | CAS: | 851067-56-6 | MF: | C22H26BrN7O | MW: | 484.39 | EINECS: | | Product Categories: | | Mol File: | 851067-56-6.mol | |
| 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one Chemical Properties |
Boiling point | 682.2±65.0 °C(Predicted) | density | 1.495±0.06 g/cm3(Predicted) | solubility | Aqueous Acid (Slightly), DMSO (Slightly, Heated), DMF (Slightly, Heated) | pka | 8.66±0.10(Predicted) | form | Solid | color | Off-White to Yellow |
| 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one Usage And Synthesis |
Uses | 6-Desacetyl-6-Bromo Palbociclib is an impurity of Palbociclib (P139900),(also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.Also, it is derived from 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one (B682195), which is used to prepare pyridino[2,3-d]pyrimidin-7(8H)-one derivatives as CDK4 and/or CDK6 inhibitors useful in the treatment of diseases. |
| 6-broMo-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one Preparation Products And Raw materials |
|